ProQR Therapeutics (PRQR) Stock Forecast & Price Target

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

$2.03

-0.02 (-0.98%)

(As of 03:57 PM ET)

ProQR Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 4 Analyst Ratings

Analysts' Consensus Price Target

$3.56
75.37% Upside

High Forecast	$5.00
Average Forecast	$3.56
Low Forecast	$1.80

Type	Current Forecast 4/17/23 to 4/16/24	1 Month Ago 3/18/23 to 3/17/24	3 Months Ago 1/17/23 to 1/17/24	1 Year Ago 4/17/22 to 4/17/23
Consensus Rating	Buy	Buy	Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$3.56	$3.80	$3.72	$4.45
Predicted Upside	75.37% Upside	82.53% Upside	121.47% Upside	72.85% Upside

Get ProQR Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

PRQR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PRQR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ProQR Therapeutics Stock vs. The Competition

Type	ProQR Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.68	2.49
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	74.08% Upside	882.15% Upside	11.23% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/14/2024	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Nakae Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$2.00 ➝ $2.50	-1.57%
3/14/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$5.00	+96.85%
11/8/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$5.00 ➝ $4.00	+196.29%
9/18/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$2.10 ➝ $1.80	+11.80%
5/17/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Kim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$5.00 ➝ $4.50	+152.81%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 04:16 PM ET.

PRQR Price Target - Frequently Asked Questions

What is ProQR Therapeutics's consensus rating and price target?: According to the issued ratings of 4 analysts in the last year, the consensus rating for ProQR Therapeutics stock is Buy based on the current 4 buy ratings for PRQR. The average twelve-month price prediction for ProQR Therapeutics is $3.56 with a high price target of $5.00 and a low price target of $1.80. Learn more on PRQR's analyst rating history.
Do Wall Street analysts like ProQR Therapeutics more than its competitors?: Analysts like ProQR Therapeutics more than other Medical companies. The consensus rating for ProQR Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how PRQR compares to other companies.
Does ProQR Therapeutics's stock price have much upside?: According to analysts, ProQR Therapeutics's stock has a predicted upside of 79.40% based on their 12-month stock forecasts.

What analysts cover ProQR Therapeutics?: ProQR Therapeutics has been rated by Chardan Capital, and HC Wainwright in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:PRQR) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ProQR Therapeutics (PRQR) Stock Forecast & Price Target

ProQR Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

PRQR Analyst Ratings By Month

PRQR Price Targets by Month

ProQR Therapeutics Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

PRQR Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info